Please send pilot project/seed grant, bridge funding and EPCR support applications to:
101 The City Drive
Bldg 56, Room 214
Orange, CA 92868
CCSG Pilot Project Funds e.g., Seed Grants allow centers to take risks; strengthen weaker scientific areas; and provide scientists the opportunity to explore innovative ideas, new collaborations and new technologies. These funds can be administered flexibly--dispensed centrally by the director and senior leaders to achieve broad strategic objectives. We make these funds accessible to all applicable areas of research, including laboratory, clinical, prevention, control, behavioral and population research for projects of relatively short duration (i.e., 1-2 years). They have been awarded to both new and established member and have been used for studies preparatory to the development of an application for independent peer-reviewed support, or to take maximum advantage of a unique research opportunity or nurture an innovative idea. These funds stimulate high priority research areas in the CFCCC, explore new directions for our Programs, and encourage cross-disciplinary translational research. Applications which support small, hypothesis-driven early clinical trials of an exploratory nature are also particularly encouraged.
The merit descriptors for review includes considerations such as the following:
The UCI Chao Family Comprehensive Cancer Center announces the availability of intramural funds to sustain cancer-related research projects that have recently lost, or face losing, extramural funding. Requests that provide evidence of a reasonable chance of funding upon resubmission of a recently reviewed application will receive a higher priority. Priority approvals will include CA designated grants from NCI, and A1 or A2 resubmissions with a priority score within 10% (prior NIH recipients) or 15% (first time applications for RPG funding) of the current payline (or if not, percentile score less than 200).
To be considered as a "peer reviewed, funded project," the responsible funding agency or organization should meet the general NIH standards of peer review and funding. These include meeting three criteria: (1) a peer review system which primarily uses external reviewers and is free of conflict of interest; (2) a ranking or rating system in the review process based on the scientific merit of the proposed research; and (3) a funding system based primarily on the peer review ranking or rating of the research applications.
Bridge support is intended for junior faculty/PIs (all series), although senior faculty/PIs are eligible to apply. A PI is eligible for the Bridge funding provided he or she meets the following requirements:
Exceptions to eligibility may be made by the Director under unusual circumstances.
Awards will be made in consultation with the Senior Leadership Committee and approved by the Director. Consideration will be given to need, assessment and the strength of the overall research program. To evaluate applications for Bridge Funding, the CFCCC requests the following:
Awards will be competitive and all applications may not be funded.
Early Phase Clinical Research Support (formerly Protocol Specific Data Management Support) is essential support for selected early phase trials conducted by investigators at the Chao Family Comprehensive Cancer Center (CFCCC). Development of investigator-initiated trials (IIT) is a major focus of the CFCCC. The CFCCC has previously reported success in increasing both the number of IIT trials and patient accrual to these trials, especially those that include a therapeutic intervention. Availability of personnel support through EPCRS funding from the Cancer Center Support Grant, P30CA062203, has been a major factor contributing to the development and execution of these trials.
This component provides support for short term, pilot (pre-phase I) and phase I clinical research studies originating from scientific investigators within the CFCCC (See http://www.cancer.gov/clinicaltrials/conducting/ncictrp/resources/glossary#p-z for clinical trial phase definitions). Preliminary data generated from these studies, which historically have been rarely funded through other mechanisms, can be used as the basis for application for support of later phase studies through competitive grants or industry. Support is not meant for all early phase trials, for later phase trials, or for studies that do that do not involve testing of an agent or device. CFCCC leadership will prioritize the member’s request for support of studies and will oversee these funds.
These funds may be used for global health studies, but must meet all eligibility criteria listed below. In addition, NIH will track all projects in this category that include foreign components and, if necessary, State Department clearance must be obtained prior to implementation. Cancer Center staff will act as the liaison between the Office of Cancer Centers and the NIH Fogarty International Center, which is responsible for coordinating all clearances.
Eligibility criteria are as follows:
Funding in these pilot and phase I clinical studies is limited to support of:
The following review criteria apply to this component: